{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:05:03Z","timestamp":1785405903688,"version":"3.56.0"},"reference-count":33,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors (TTI) has emerged as a promising strategy for unresectable hepatocellular carcinoma (uHCC); however, its impact on liver function and the prognostic role of baseline albumin\u2013bilirubin (ALBI) grade remain insufficiently defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To compare the effects of combined therapy and transarterial chemoembolization (TACE) alone on liver function in uHCC patients, and to evaluate the prognostic value of baseline ALBI grade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This retrospective study enrolled uHCC patients treated with TTI or TACE alone between January 2018 and December 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The primary outcome was the time to progression of baseline ALBI grade, with secondary outcomes including overall survival (OS) and progression-free survival (PFS) of patients. Survival outcomes were analyzed using the Kaplan\u2013Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 162 patients (TTI group: 68; TACE alone group: 94) were included. The TTI group showed a significantly longer median time to progression of baseline ALBI grade than the TACE alone group (19.0\u2009months vs 11.6\u2009months,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.004). Subgroup analyses revealed similar benefits of the TTI group (11.3\u2009months vs 5.0\u2009months for baseline ALBI grade 1,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.015; 20.0\u2009months vs 14.7\u2009months for baseline ALBI grade 2,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.025). Patients in the TTI group demonstrated superior median OS (42.2\u2009months vs 22.0\u2009months for baseline ALBI grade 1,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.077; 22.6\u2009months vs 13.5\u2009months for baseline ALBI grade 2,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.001) and longer median PFS (11.7\u2009months vs 6.8\u2009months for baseline ALBI grade 1,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.148; 8.4\u2009months vs 4.9\u2009months for baseline ALBI grade 2,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.022) compared to the TACE alone group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>TTI therapy preserved liver function for a longer duration and achieved better survival outcomes than TACE alone in uHCC patients, particularly benefiting those with baseline ALBI grade 2.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359261470015","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:20:46Z","timestamp":1785216046000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of TACE combined with targeted and immune therapy on liver function and prognosis in unresectable hepatocellular carcinoma patients: the significance of baseline albumin-bilirubin grade"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0427-7877","authenticated-orcid":false,"given":"Yiwan","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology &amp; Interventional Medicine, Wuhan, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology &amp; Interventional Medicine, Wuhan, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology &amp; Interventional Medicine, Wuhan, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Pu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology &amp; Interventional Medicine, Wuhan, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology &amp; Interventional Medicine, Wuhan, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-1417","authenticated-orcid":false,"given":"Chuansheng","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology &amp; Interventional Medicine, Wuhan, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3597-4166","authenticated-orcid":false,"given":"Xuefeng","family":"Kan","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue #1277, Wuhan 430022, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology &amp; Interventional Medicine, Wuhan 430022, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue #1277, Wuhan 430022, China"},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology &amp; Interventional Medicine, Wuhan 430022, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01200-4"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000509424"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.807102"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01712.x"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003311"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01235-0"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102622"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12626"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000462199"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.9151"},{"issue":"6","key":"e_1_3_4_14_2","first-page":"610","article-title":"Prognostic efficacy of the albumin-bilirubin score and treatment outcomes in hepatocellular carcinoma: a large-scale, multi-center real-world database study","volume":"13","author":"Kim KP","year":"2024","unstructured":"Kim KP, Kim KM, Ryoo BY, et al. Prognostic efficacy of the albumin-bilirubin score and treatment outcomes in hepatocellular carcinoma: a large-scale, multi-center real-world database study. Liver Cancer 2024; 13(6): 610\u2013628.","journal-title":"Liver Cancer"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/1073274819865269"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211039928"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000529996"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.09.026"},{"key":"e_1_3_4_20_2","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0 https:\/\/dctd.cancer.gov\/research\/cteptrials\/for-sites\/adverse-events (2017 accessed 29 April 2025)."},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000466"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-018-1500-9"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S213432"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25522"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-019-1251-y"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15487"},{"issue":"2","key":"e_1_3_4_27_2","article-title":"Effect of ramucirumab on ALBI grade in patients with advanced HCC: results from REACH and REACH-2","volume":"3","author":"Kudo M","year":"2021","unstructured":"Kudo M, Galle PR, Brandi G, et al. Effect of ramucirumab on ALBI grade in patients with advanced HCC: results from REACH and REACH-2. JHEP Rep 2021; 3(2): 100215.","journal-title":"JHEP Rep"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2419993"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12484-3"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.874473"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0718-5"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-019-00182-w"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.2478\/aite-2025-0020"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2548"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261470015","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261470015","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261470015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:46:32Z","timestamp":1785404792000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261470015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"alternative-id":["10.1177\/17588359261470015"],"URL":"https:\/\/doi.org\/10.1177\/17588359261470015","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"17588359261470015"}}